PODCAST: David Diamond, PhD discusses Forgotten Baby Syndrome

Approval is based on a study in 116 adult and pediatric male patients with either severe hemophilia A or severe hemophilia B, both without inhibitors.

Overall, 2 doses of TAK-003 successfully induced the production of neutralizing antibodies against all 4 dengue serotypes in at least 90% of adults, children, and adolescents, regardless of whether they were seronegative or seropositive at baseline.

Daily intervention intensity was not associated with significant effect sizes for any of the 4 intervention types, though technology-based interventions showed the largest positive association.

Brittany Bruggeman, MD, highlighted the ability to predict type 1 diabetes months to years in advance through islet autoantibodies, and how the pediatrician can play a role.